Acetazolamide attenuates cardiac fibrosis induced by aortic constriction through inhibiting transforming growth factor-β1/Smad2 signaling pathway in mice

Huo,Qianqian; Wang,Ting; Wang,Tao; Zhang,Rui

doi:10.3892/etm.2019.7210

Acetazolamide attenuates cardiac fibrosis induced by aortic constriction through inhibiting transforming growth factor-β1/Smad2 signaling pathway in mice

Authors:
- Qianqian Huo
- Ting Wang
- Tao Wang
- Rui Zhang
View Affiliations

Affiliations: Department of Cardiology, Jining Νo. 1 People's Hospital, Jining, Shandong 272011, P.R. China, Department of Cardiology, Zoucheng People's Hospital, Zoucheng, Shandong 273500, P.R. China, Department of Cardiology, Jiyang People's Hospital, Jiyang, Shandong 251400, P.R. China, Department of Cardiology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China
Published online on: January 28, 2019 https://doi.org/10.3892/etm.2019.7210
Pages: 2317-2321
Copyright: © Huo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect and mechanism of acetazolamide on cardiac fibrosis induced by transverse aortic constriction (TAC) were investigated. C57BL/6 mice were subjected to TAC or sham operation and then were orally gavaged with acetazolamide (20 mg/kg/day). After 4 weeks of operation, cardiac function was detected by echocardiography. Interstitial fibrosis was stained with Masson's trichrome. The expression of α-smooth muscle actin (α-SMA), collagen I, transforming growth factor-β1 (TGF-β1) and Smad2 were measured by western blotting. The TAC mice displayed significant cardiac dysfunction and fibrosis. The expression of α-SMA, collagen I, TGF-β1 and p-Smad2 in the TAC group was higher than those in the sham group. By contrast, acetazolamide administration inhibited interstitial fibrosis, as well as improved cardiac dysfunction induced by TAC. Acetazolamide also reduced the expression of α-SMA, collagen I, TGF-β1 and p-Smad2 in the TAC mice. Acetazolamide was able to attenuate cardiac fibrosis and improve cardiac dysfunction. The molecular mechanism involved in the anti-fibrotic effect of acetazolamide possibly was through inhibiting TGF-β1/Smad2 signaling pathway.

View Figures

View References

1	Creemers EE and Pinto YM: Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 89:265–272. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 71:549–574. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bar A, Cies J, Stapleton K, Tauber D, Chopra A and Shore PM: Acetazolamide therapy for metabolic alkalosis in critically ill pediatric patients. Pediatr Crit Care Med. 16:e34–e40. 2015. View Article : Google Scholar : PubMed/NCBI
4	Fontana V, Santinelli S, Internullo M, Marinelli P, Sardo L, Alessandrini G, Borgognoni L, Ferrazza AM, Bonini M and Palange P: Effect of acetazolamide on post-NIV metabolic alkalosis in acute exacerbated COPD patients. Eur Rev Med Pharmacol Sci. 20:37–43. 2016.PubMed/NCBI
5	Bremer AM, Yamada K and West CR: Ischemic cerebral edema in primates: Effects of acetazolamide, phenytoin, sorbitol, dexamethasone, and methylprednisolone on brain water and electrolytes. Neurosurgery. 6:149–154. 1980. View Article : Google Scholar : PubMed/NCBI
6	Apostolo A, Agostoni P, Contini M, Antonioli L and Swenson ER: Acetazolamide and inhaled carbon dioxide reduce periodic breathing during exercise in patients with chronic heart failure. J Card Fail. 20:278–288. 2014. View Article : Google Scholar : PubMed/NCBI
7	Li XJ, Xiang Y, Ma B and Qi XQ: Effects of acetazolamide combined with or without NaHCO₃ on suppressing neoplasm growth, metastasis and aquaporin-1 (AQP1) protein expression. Int J Mol Sci. 8:229–240. 2007. View Article : Google Scholar
8	Lin PT, Chen WH, Zheng H, Lai ZM and Zhang LC: Involvement of AQP 1 in the cardio-protective effect of remifentanil post-conditioning in ischemia/reperfusion rats. Int J Clin Exp Med. 8:12736–12745. 2015.PubMed/NCBI
9	Dobaczewski M, Chen W and Frangogiannis NG: Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 51:600–606. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wu M, Han M, Li J, Xu X, Li T, Que L, Ha T, Li C, Chen Q and Li Y: 17beta-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation. Eur J Pharmacol. 616:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
11	Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlüter KD and Böhm M: Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 283:H1253–H1262. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K and Imaizumi T: Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 106:130–135. 2002. View Article : Google Scholar : PubMed/NCBI
13	Miller AD and Tyagi SC: Mutation in collagen gene induces cardiomyopathy in transgenic mice. J Cell Biochem. 85:259–267. 2002. View Article : Google Scholar : PubMed/NCBI
14	Bujak M and Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 74:184–195. 2007. View Article : Google Scholar : PubMed/NCBI
15	Lei B, Hitomi H, Mori T, Nagai Y, Deguchi K, Mori H, Masaki T, Nakano D, Kobori H, Kitaura Y, et al: Effect of efonidipine on TGF-β1-induced cardiac fibrosis through Smad2-dependent pathway in rat cardiac fibroblasts. J Pharmacol Sci. 117:98–105. 2011. View Article : Google Scholar : PubMed/NCBI
16	Huang XR, Chung AC, Yang F, Yue W, Deng C, Lau CP, Tse HF and Lan HY: Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension. 55:1165–1171. 2010. View Article : Google Scholar : PubMed/NCBI
17	Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Yan BP, Yu CM and Lan HY: Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc Res. 99:665–673. 2013. View Article : Google Scholar : PubMed/NCBI